39 results about "Reduced appetite" patented technology

Provided herein are methods and compositions related to reducing appetite. In some aspects, provided herein are methods of reducing appetite in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

The present invention belongs to the field of pharmaceutical synthesis, and specifically relates to salviphorol derivatives and their application in drugs for treating cancer cachexia. Salviphorol compounds include compounds represented by formula (X) and / or formula (Y), or pharmaceutically acceptable salts or optical isomers of the compounds represented by formula (X) and / or formula (Y). The present invention also provides a pharmaceutical composition for treating cachexia diseases, and its application in the preparation of drugs for treating cancer cachexia, including muscle atrophy caused by tumor tissues, fat reduction caused by tumor tissues, reduced appetite caused by tumor tissues, inflammatory responses caused by tumor tissues, and cancer cachexia caused by digestive tract-related cancers, liver cancer, lung cancer, and colon cancer. The present invention also provides its application in the preparation of drugs or inhibitors for treating or inhibiting muscle atrophy, drugs or inhibitors for inhibiting or alleviating adipocyte lipolysis, and drugs or inhibitors for inhibiting or alleviating weight loss or reduction.

The invention relates to a Chinese medicine composition, and discloses a medicine composition for treating chronic atrophic gastritis, a preparation method thereof and a use thereof. The medicine composition is prepared from effective ingredients and pharmaceutically acceptable auxiliary materials, wherein the effective ingredients are prepared from raw materials in the following weight ratio: 4-8g of red ginseng, 12-18g of white atractylodes, 4-8g of notoginseng, 4-6g of angelica, 8-12g of curcuma, 12-18g of coix seed, 12-18g of fritillaria thunbergii, 8-12g of dendrobium, 12-18g of falanghai, and 8-12g of salacia. Red ginseng and notoginseng are extracted by ethanol refluxing to obtain red ginseng and notoginseng extracts; red ginseng, notoginseng residues and the remaining eight raw materials are boiled and extracted with water, and the filtrate is concentrated and then added with the red ginseng and notoginseng extracts to prepare the preparation. This combination warms the spleen and replenishes qi, removes dampness and resolves blood stasis. It is used for chronic atrophic gastritis caused by spleen and stomach yang deficiency, internal obstruction of dampness and blood stasis, or accompanied by intestinal metaplasia and intraepithelial neoplasia. Symptoms include fullness in the epigastric region, noisy or dull pain in the stomach, decreased appetite, etc. It has a significant therapeutic effect on spleen and stomach yang deficiency, internal obstruction of dampness and blood stasis, etc.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a first composition comprising a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures, a crosslinking compound, a foaming agent and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, a second composition comprising citric acid. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The present invention provides an irisin polypeptide, as well as its expression nucleic acid, recombinant vector, recombinant cell, pharmaceutical composition, food composition, and use thereof in preparing drugs for treating and preventing metabolic-related diseases in subjects; and the irisin polypeptide plays an obvious role in regulating body metabolism, controlling blood sugar levels, enhancing muscle strength, reducing body weight, and reducing appetite, and can be widely used in the fields of medicine, food, health care products, etc.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention belongs to the technical field of traditional Chinese medicine, and in particular to a Chinese medicine composition for treating depression. The Chinese medicine composition is mainly prepared from astragalus, codonopsis, ophiopogon, polygonum multiflorum, epimedium, kudzu root, angelica, salvia miltiorrhiza, honeysuckle, seaweed, kelp, oyster, and immature bitter orange. The Chinese medicine composition of the present invention can significantly improve the symptoms of loss of appetite and weight loss in depression model rats, improve the symptoms of loss of interest in depression model rats, effectively alleviate the symptoms of increased inflammatory factors TNF-α, IL-1β, and INF-γ caused by depression, significantly increase the levels of 5-hydroxytryptamine and dopamine in rat cortex and hippocampus, and effectively treat depression.

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention discloses a flaxseed composition capable of reducing triglyceride and facilitating obesity prevention and a preparation method of the flaxseed composition, and relates to the field of chemistry. According to the flaxseed composition capable of reducing triglyceride and contributing to obesity prevention and the preparation method of the flaxseed composition, the composition consists of the following components: 30-90% of flaxseeds; 10%-40% of tartary buckwheat; 0%-50% of oligosaccharide; the preparation method comprises the following steps: mixing the flaxseeds, the tartary buckwheat and the oligosaccharide according to the proportion in claim 1; crushing and screening to ensure that all the components are fully and uniformly mixed; and drying the mixture to obtain a final product. According to the composition, by reducing the triglyceride level, the risk of cardiovascular diseases is effectively reduced, and the overall metabolic state is improved; by promoting fat oxidation and improving insulin sensitivity, normal blood glucose and lipid levels can be maintained; the composition is helpful for reducing body weight and preventing obesity by regulating energy metabolism, reducing appetite and improving intestinal microbial environment.

The invention discloses an application of bifidobacterium animalis subsp. Lactis SS9 in preparation of a product for preventing and treating stress obesity. The bifidobacterium animalis subsp. Lactis SS9 obtained by screening can remarkably relieve obesity induced by combination of chronic pressure and high-fat diet, and the obesity is represented by slowing down weight increase, reducing appetite, improving blood fat, up-regulating GLP-1 and insulin secretion and effectively relieving anxiety-like and depression-like behaviors. Researches find that the strain can regulate the hypothalamic-pituitary-adrenal axis activation level, improve secretion imbalance of hormones such as CRH, ACTH and CORT, restore expression of appetite regulation factors such as NPY / AgRP / POMC of hypothalamic and relieve emotional eating behaviors. In addition, the strain can also reduce the systemic inflammation level, recover the diversity of intestinal flora and improve the proportion of beneficial bacteria. The invention provides the probiotics with multiple effects of regulating emotion, controlling body weight and improving metabolic disorder, and a new strategy is provided for preventing and treating stress-related obesity.

The invention provides a preparation method of a plant extract for providing satiety. The preparation method comprises the following steps: (1) mixing powdery verbena citriodora, gymnema latifolium or roselle with an extraction solvent A, and soaking; (2) performing reflux extraction on the mixed solution soaked in the step (1) at 40-80 DEG C; (3) carrying out solid-liquid separation, collecting reflux, and carrying out low-pressure concentration; and (4) adsorbing the concentrated solution through D101 macroporous adsorption resin, eluting with water for the first time, discarding the eluent, eluting with an ethanol water solution with the ethanol volume fraction of 40-60% for the second time, collecting the eluent, and concentrating and drying to obtain the gymnema latifolium extract or the roselle extract. The plant extract prepared by the preparation method of the satiety plant extract provided by the invention can help to reduce appetite intake by influencing the level of appetite regulating peptides secreted by in-vivo adipose tissues or digestive tracts, promote bioactive components with the idea of health and weight loss, and can significantly reduce the level of total cholesterol and LDL cholesterol.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

The invention provides a plant extract compound for providing satiety. The plant extract compound is prepared from the following components in parts by weight: 1 part of lemon verbena extract, 0.5-2 parts of gymnema latifolium extract and 0.5-2 parts of roselle extract. The plant extract compound is prepared from the following components in parts by weight: 1 part of lemon verbena extract, 0.5-2 parts of gymnema latifolium extract and 0.5-2 parts of roselle extract. The satiety plant extract compound provided by the invention can significantly reduce the total cholesterol and LDL cholesterol level, improve the HDL cholesterol level and reduce the food intake through the bioactive components which influence the appetite regulation peptide level secreted by in-vivo fat tissues or digestive tracts, help to reduce appetite intake and promote the idea of health and weight loss, so that the total cholesterol and LDL cholesterol level can be significantly reduced, the HDL cholesterol level can be improved, and the food intake can be reduced. Reducing the blood glucose level and reducing the expression of leptin hormone, thereby reversing the overexpression of leptin and possibly eliminating resistance to leptin; accumulation of triglyceride in 3T3-L1 fat cells can be reduced, and cytoplasm AMPK can be activated; appetite can be reduced or satiety can be increased by affecting the level of peptides secreted by the digestive tract and adipose tissue.

The invention provides a composition comprising the following components: a hydrogel material, monovalent or divalent cation salt, a filler, a disintegrating agent and a lubricant. The composition is scientific and reasonable in formula combination, free of toxic and side effects on human bodies and easy to prepare. The product prepared from the composition disclosed by the invention can simultaneously have good preparation performance, disintegration performance and gelling performance through specific components, proportion and preparation process, is relatively high in stability of product quality, is suitable for large-scale application and development, and can occupy the space in the stomach, promote satiety and reduce appetite after being eaten; therefore, the purposes of weight management, obesity treatment, blood sugar control, diabetes prevention and treatment, blood cholesterol reduction and the like are achieved.

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and / or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures thereof, a crosslinking compound, a foaming agent, and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, an acid selected from tartaric acid, succinic acid, ascorbic acid, and mixtures thereof. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The present invention primarily relates to a combination agent for reducing appetite and / or for providing a feeling of satiety and / or for reducing energy intake and / or for reducing body weight. In addition, the present invention relates to a medical use of the combination agent, in particular for the treatment of overweight and obesity and for the prevention of cardiovascular disease, stroke, diabetes, and joint damage and wear of the spine, and to a non-therapeutic use of the combination agent. In particular, the focus of the present invention is on the use of the combination agent to provide a feeling of satiety and / or to reduce energy intake and / or to reduce body weight. Finally, the present invention relates to the use of the combination agent for the preparation of an orally consumable preparation or food ingredient and an orally consumable preparation or food ingredient prepared therefrom.

The invention discloses a composite liver and kidney protective agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The protective agent is prepared from 10%-20% of inosine, 15%-25% of glutamic acid, 10%-15% of cysteine, 15%-20% of glycine, 5%-10% of a coenzyme compound, 10%-20% of small molecule peptide and auxiliary materials. The preparation method comprises the steps of premixing, low-temperature homogenization, spray drying and preparation forming, and uniform distribution of components is ensured through a spray drying technology. The traditional Chinese medicine composition plays a role through a three-stage mechanism of fat removal, repair and regeneration, reduces lipid deposition, scavenges free radicals, repairs hepatocytes and promotes regeneration. The traditional Chinese medicine composition can be used for treating or preventing liver and kidney diseases such as non-alcoholic fatty liver, viral hepatitis and cirrhosis, relieving symptoms such as anorexia, jaundice and bleeding, dispelling the effects of alcohol, protecting the liver and enhancing immunity. The proportion of natural components of the protective agent is more than 80%, the safety is high, multiple targets are synergistic, and the curative effect is superior to that of a single-component medicine.

The invention discloses application of leuconostoc mesenteroides and / or metabolites of the leuconostoc mesenteroides to preparation of a composition for reducing body fat, reducing appetite, promoting ketone mass or regulating fasting blood glucose, wherein the leuconostoc mesenteroides is leuconostoc mesenteroides subsp. Mesenteroides with the preservation number of DSM34443.

Provided herein are methods and compositions related to reducing appetite. In some aspects, provided herein are methods of reducing appetite in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

A compound comprising a peptide chain which is an amylin analogue, a terminal-NH2 group bound to the C-terminus of the peptide chain, and an alkylene or alkenylene chain attached to the other end of the peptide chain, or a derivative of the compound; or a salt or solvate of the compound or derivative. The compounds, derivatives, and salts, and related compositions are useful for preventing or treating diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease, improving insulin release, improving carbohydrate metabolism, improving blood lipid profile, improving carbohydrate tolerance, reducing appetite, and preventing or treating diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease in a subject. Reducing food intake and / or reducing caloric intake and related purposes.

This invention discloses a strain of *Drugella*, its produced polysaccharide, and its applications. The *Drugella* G3 strain of this invention has the preservation number CCTCC NO: M 2024137. Its extracellular polysaccharide TDG3, as a TLR4 / DC-SIGN dual receptor agonist, exhibits a significant effect in reducing body weight. The extracellular polysaccharide TDG3 of this invention can significantly reduce appetite, decrease food intake, reduce body weight, and reduce adipose tissue content in mice. It can also alleviate or prevent obesity-induced hepatic steatosis. It is safe and non-toxic, suitable for preparing lipid-lowering and weight-loss drugs, and has good clinical application value and broad application prospects.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

Compositions comprising fatty acid analogs are provided for treating conditions involving impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, and convulsion, and other conditions. Methods for the diagnosis and monitoring of impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, convulsion, and other conditions are also provided.

The invention relates to the technical field of medical health, in particular to a method for constructing a fat-sweet and cold type functional dyspepsia mouse model, successfully constructs a functional dyspepsia mouse model capable of simulating a high-fat and cold diet mode in modern society, and overcomes the defect that an existing model only depends on a single diet factor. The model not only can effectively simulate the symptoms of the functional dyspepsia, such as anorexia, gastric emptying delay, intestinal tract propulsion function decline and the like, but also can provide a new perspective for further researching the pathogenesis of the functional dyspepsia in combination with the dyspepsia theory of traditional Chinese medicine.

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and / or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexylamine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.